Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Edward Pohodich

Nurse Practitioner Connellsville, PA Nurse Practitioner

NPI 1609867118 CMS profile 10448061

2616 Memorial Blvd Ste B, Connellsville, PA 15425

Open in the dashboard

General payments

$4,661

180 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Pohodich of Connellsville, PA is reported in the CMS Open Payments database as having received $4,661 across 180 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $191 2
2023 General $694 33
2022 General $2,814 126
2021 General $963 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Pohodich
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Edward Pohodich were reported at $191. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Edward Pohodich Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $963 $135 $40–$426 $132
2022 $2,814 $152 $48–$470 $149
2023 $694 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $191 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $884 24 payments
  2. Novo Nordisk Inc $856 34 payments
  3. AbbVie, Inc. $482 21 payments
  4. Biohaven Pharmaceutical Holding Company Ltd. $449 14 payments
  5. Biohaven Pharmaceuticals, Inc. $372 4 payments
  6. Lilly USA, LLC $362 19 payments
  7. E.R. Squibb & Sons, L.L.C. $171 7 payments
  8. GlaxoSmithKline, LLC. $171 11 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $161 14 payments
  10. Amgen Inc. $132 3 payments
  11. Other $621 29 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,652 179 payments
  2. Education $9 1 payment
Products named General payments · program years 2021–2025
  1. NURTEC ODT $822 18 payments
  2. FARXIGA $651 20 payments
  3. RYBELSUS $635 31 payments
  4. Ozempic $569 30 payments
  5. UBRELVY $368 13 payments
  6. QULIPTA $220 8 payments
  7. BREZTRI $218 3 payments
  8. JARDIANCE $199 13 payments
  9. ELIQUIS $171 7 payments
  10. TRELEGY ELLIPTA $171 11 payments
  11. Other $1,563 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

695

Median for Nurse Practitioner: 389

Drug cost

$104,541

Median for Nurse Practitioner: $21,885

Branded share of claims

26.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 20 $20,173
Eliquis Apixaban Brand 30 $16,124
Jardiance Empagliflozin Brand 25 $14,082
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 19 $13,015
Tradjenta Linagliptin Brand 12 $6,533
Pantoprazole Sodium Generic 28 $5,848
Omeprazole Generic 33 $2,875
Atorvastatin Calcium Generic 49 $2,614
Anastrozole Generic 11 $2,468
Rosuvastatin Calcium Generic 19 $2,261

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record